Elizabeth S. Klings, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, New York University School of Medicine




Dr. Klings is an Associate Professor in the Department of Medicine. She is the Director of the Center for Excellence in Sickle Cell Disease and the Director of the Pulmonary Hypertension at BUSM/Boston Medical Center. She has an outpatient clinical practice focused on patients with pulmonary hypertension and those with pulmonary complications of sickle cell disease. She attends in the Medical Intensive Care Unit and on the Pulmonary Hypertension Consultation Service at Boston Medical Center. As Director of the largest sickle cell center in New England, Dr. Klings has created numerous new clinical programs for our patients and has expanded the clinical trials program.

Dr. Klings’ research since fellowship has focused on pathogenesis of pulmonary vascular complications of sickle cell disease. She is an NIH-funded Principal Investigator .in the Pulmonary Center collaborating with numerous other investigators across the medical campus. She has phenotypically screened over 200 sickle cell patients at Boston Medical Center for the presence of pulmonary hypertension and currently investigating the roles of disease modulators including sleep-disordered breathing and venous thromboembolism in the endothelial and vascular dysfunction these patients experience. Known internationally as a leader in the care and treatment of patients with sickle cell disease, she was first author of the American Thoracic Society sponsored clinical guidelines for Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease. She recently chaired an ATS sponsored workshop to define clinical and research priorities in sickle cell lung disease and serves on the NHLBI Sickle Cell Disease Advisory Committee.

Member
Boston University
Pulmonary Center


Program Director
Boston University
Center of Excellence in Sickle Cell Disease


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




Protocol # STERIO-SCD, A Phase lib Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases
03/20/2018 - 09/19/2023 (Subcontract PI)
University of Pittsburgh Bayer HealthCare


Protocol #APD811-303: A Study Evaluating the Long-Term Efficacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
02/06/2019 - 02/06/2022 (PI)
United Therapeutics Corporation


Assessing the effectiveness of anti-sickling agents for sickle hemoglobin and red blood cells
02/01/2016 - 01/31/2022 (PI)
General Hospital Corp d/b/a Massachusetts General Hospital


A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension
12/12/2014 - 12/31/2020 (PI)
Arena Pharmaceuticals Inc.


A StuDy eVAluatiNg the EfficaCy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
11/30/2018 - 11/30/2020 (PI)
United Therapeutics Corporation


Hematopoietic Stem Cell Transplantation for Young Adults with Sickle Cell Disease
09/01/2015 - 07/31/2020 (Subcontract PI)
Emory University NIH NHLBI
5U01HL128566-03

Protocol # 402-C-1602, An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension.
07/27/2017 - 07/26/2020 (PI)
Reata Pharmaceuticals, Inc.


The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo
07/15/2015 - 07/14/2020 (PI)
Actelion Pharmaceuticals, Ltd.


Protocol # AC-055-512 RETRO: A Retrospective, multicEnter charT Review to collect dOsing information of PAH background medication in subject who participated in the AC-055-302 (SERAPHIN) double-blind
07/26/2018 - 05/31/2020 (PI)
Actelion Pharmaceuticals, Ltd.


A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension
05/30/2014 - 05/31/2020 (PI)
Reata Pharmaceuticals, Inc.


Showing 10 of 30 results. Show All Results

SEG101 (STAND): A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and …
01/23/2020 - 03/01/2028 (PI)
Novartis Pharma Corp

1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCDCARRE Trial)
05/01/2020 - 04/30/2026 (PI)
University of Pittsburgh NIH-NHLBI

4202-HEM-301: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE).
03/24/2021 - 03/23/2024 (PI)
Forma Therapeutics, Inc.


Title


Yr Title Project-Sub Proj Pubs
2013 Protein biomarkers of pulmonary hypertension in sickle cell disease 5R21HL107993-02 3
2012 Protein biomarkers of pulmonary hypertension in sickle cell disease 1R21HL107993-01A1 3
2011 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-15-5116 259
2010 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-14-6816 259
2009 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-13-6167 259
2009 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-05 7
2008 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 5P41RR010888-12-5241 259
2008 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-04 7
2007 COMPARATIVE PROTEOMICS OF SICKLE CELL DISEASE-RELATED PULMONARY HYPERTENSION 2P41RR010888-11-8062 259
2007 Gene polymorphism in chronic sickle cell lung disease 5K23HL079003-03 7
Showing 10 of 17 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Cramer-Bour C, Peterson J, Walsh B, Klings ES. Common Complications of Sickle Cell Disease: A Simulation-Based Curriculum. MedEdPORTAL. 2021 04 02; 17:11139. PMID: 33851012; PMCID: PMC8034233; DOI: 10.15766/mep_2374-8265.11139;
     
  2. Gillmeyer KR, Miller DR, Glickman ME, Qian SX, Klings ES, Maron BA, Hanlon JT, Rinne ST, Wiener RS. Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease. Pulm Circ. 2021 Apr-Jun; 11(2):20458940211001714.View Related Profiles. PMID: 33868640; PMCID: PMC8020250; DOI: 10.1177/20458940211001714;
     
  3. Cramer-Bour C, Ruhl AP, Nouraie SM, Emeh RO, Ruopp NF, Thein SL, Weir NA, Klings ES. Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease. Eur J Haematol. 2021 Mar 01. PMID: 33650125
     
  4. Lui JK, Mesfin N, Tugal D, Klings ES, Govender P, Berman JS. Critical Care of Patients With Cardiopulmonary Complications of Sarcoidosis. J Intensive Care Med. 2021 Feb 22; 885066621993041.View Related Profiles. PMID: 33611981
     
  5. Minniti CP, Zaidi AU, Nouraie M, Manwani D, Crouch GD, Crouch AS, Callaghan MU, Carpenter S, Jacobs C, Han J, Simon J, Glassberg J, Gordeuk VR, Klings ES. Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Adv. 2021 01 12; 5(1):207-215. PMID: 33570644; PMCID: PMC7802524; DOI: 10.1182/bloodadvances.2020003456;
     
  6. Gillmeyer KR, Nunez ER, Rinne ST, Qian SX, Klings ES, Wiener RS. Development and Validation of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data. Chest. 2021 May; 159(5):1986-1994.View Related Profiles. PMID: 33345949; PMCID: PMC8129727; DOI: 10.1016/j.chest.2020.12.010;
     
  7. Yeh GY, Litrownik D, Wayne PM, Beach D, Klings ES, Reyes Nieva H, Pinheiro A, Davis RB, Moy ML. BEAM study (Breathing, Education, Awareness, Movement): a randomised controlled feasibility trial of tai chi exercise in patients with COPD. BMJ Open Respir Res. 2020 11; 7(1).View Related Profiles. PMID: 33219007; PMCID: PMC7682460; DOI: 10.1136/bmjresp-2020-000697;
     
  8. Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN, Gordeuk VR, Kanter J, Klings ES, Lipato T, Manwani D, Scullin B, Yermilov I, Smith WR. Development of a Severity Classification System for Sickle Cell Disease. Clinicoecon Outcomes Res. 2020; 12:625-633. PMID: 33149635; PMCID: PMC7604906; DOI: 10.2147/CEOR.S276121;
     
  9. Gupta VK, Strykowski R, Scarpato B, Lawrence R, Khan SL, Patel J, Nouraie SM, Cohen RT, Sloan JM, Klings ES. The effect of anticoagulant choice on venous thromboembolism recurrence and bleeding in sickle cell disease. Am J Hematol. 2020 Jul 03.View Related Profiles. PMID: 32619024
     
  10. Gillmeyer KR, Rinne ST, Glickman ME, Lee KM, Shao Q, Qian SX, Klings ES, Maron BA, Hanlon JT, Miller DR, Wiener RS. Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015. Circ Cardiovasc Qual Outcomes. 2020 05; 13(5):e005993.View Related Profiles. PMID: 32393128; PMCID: PMC7344878; DOI: 10.1161/CIRCOUTCOMES.119.005993;
     
Showing 10 of 70 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 70 publications over 23 distinct years, with a maximum of 7 publications in 2020

YearPublications
19992
20003
20014
20022
20031
20041
20052
20062
20072
20082
20093
20102
20113
20123
20131
20146
20154
20162
20173
20185
20195
20207
20215
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

anemia, sickle cell
endothelium
pulmonary hypertension

Available to Mentor as: (Review Mentor Role Definitions):
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Klings's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department